Gyre Therapeutics adds three directors to board effective August 1, 2026

Gyre Therapeutics, Inc. (Nasdaq: GYRE) said on July 16, 2026 that its board had appointed three new directors, effective August 1, 2026: Yue Xiong, Ph.D., the Company's Chief Scientific Officer; Maxwell Kirkby; and Claire Weston, Ph.D.¹ According to the company, the additions were meant to broaden the board's reach into scientific, clinical development, and cross-border biopharmaceutical operating expertise¹.

Under the board's classified structure, Dr. Xiong will serve as a Class I director, with a term expiring at the Company's 2028 annual meeting of stockholders.¹ Mr. Kirkby will serve as a Class II director, with a term expiring at the Company's 2029 annual meeting of stockholders, and has also been appointed to the Compensation Committee of the Board.¹ Dr. Weston will serve as a Class III director, with a term expiring at the Company's 2027 annual meeting of stockholders, and has been appointed to the Audit Committee of the Board.¹

On compensation, the company disclosed that Kirkby and Weston will each be granted options for 40,000 shares of common stock that vest monthly over three years, and both will receive cash pay under Gyre's standard non-employee director compensation policy described in its April 27, 2026 proxy statement¹. Both new outside directors are also entering into the company's standard indemnification agreement, the same form filed as an exhibit to an October 2023 8-K¹, while Xiong already has an indemnification agreement from his CSO appointment and will not receive additional board compensation¹.

The filing stated there were no arrangements or understandings behind any of the appointments, no family relationships with existing directors or officers, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K¹.